{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:13:58Z","timestamp":1794849238879,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Myrtelle, Inc. New York, New York"},{"name":"Myrtelle, Inc., New York, New York"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41591-025-03919-w","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T09:03:07Z","timestamp":1758013387000},"page":"3772-3779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Oligodendrocyte-targeted adeno-associated virus gene therapy for Canavan disease in children: a phase 1\/2 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7296-4587","authenticated-orcid":false,"given":"Paola","family":"Leone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Lober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7691-2637","authenticated-orcid":false,"given":"Olga","family":"Flamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8233-5485","authenticated-orcid":false,"given":"Kim M.","family":"Cecil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-3356","authenticated-orcid":false,"given":"Christopher G.","family":"Janson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"3919_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/archneurpsyc.1931.02230020085005","volume":"25","author":"MM Canavan","year":"1931","unstructured":"Canavan, M. M. Schilder\u2019s encephalitis periaxialis diffusa: report of a case of a child aged sixteen and one-half months. Arch. Neurol. Psychiatry 25, 299\u2013308 (1931).","journal-title":"Arch. Neurol. Psychiatry"},{"key":"3919_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/1531-8249(200007)48:1<27::AID-ANA6>3.0.CO;2-6","volume":"48","author":"P Leone","year":"2000","unstructured":"Leone, P. et al. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann. Neurol. 48, 27\u201338 (2000).","journal-title":"Ann. Neurol."},{"key":"3919_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/BF00711906","volume":"16","author":"R Matalon","year":"1993","unstructured":"Matalon, R., Kaul, R. & Michals, K. Canavan disease: biochemical and molecular studies. J. Inherit. Metab. Dis. 16, 744\u2013752 (1993).","journal-title":"J. Inherit. Metab. Dis."},{"key":"3919_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1385\/JMN:15:2:61","volume":"15","author":"MH Baslow","year":"2000","unstructured":"Baslow, M. H. Canavan\u2019s spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease. J. Mol. Neurosci. 15, 61\u201369 (2000).","journal-title":"J. Mol. Neurosci."},{"key":"3919_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.nbd.2016.10.001","volume":"96","author":"JS Francis","year":"2016","unstructured":"Francis, J. S. et al. N-Acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Neurobiol. Dis. 96, 323\u2013334 (2016).","journal-title":"Neurobiol. Dis."},{"key":"3919_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/ped.12422","volume":"56","author":"H Hoshino","year":"2014","unstructured":"Hoshino, H. & Kubota, M. Canavan disease: clinical features and recent advances in research. Pediatr. Int. 56, 477\u2013483 (2014).","journal-title":"Pediatr. Int."},{"key":"3919_CR7","doi-asserted-by":"publisher","first-page":"661928","DOI":"10.3389\/fncel.2021.661928","volume":"15","author":"A Lotun","year":"2021","unstructured":"Lotun, A., Gessler, D. J. & Gao, G. Canavan disease as a model for gene therapy-mediated myelin repair. Front. Cell. Neurosci. 15, 661928 (2021).","journal-title":"Front. Cell. Neurosci."},{"key":"3919_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/ana.20787","volume":"59","author":"CG Janson","year":"2006","unstructured":"Janson, C. G. et al. Mild-onset presentation of Canavan\u2019s disease associated with novel G212A point mutation in aspartoacylase gene. Ann. Neurol. 59, 428\u2013431 (2006).","journal-title":"Ann. Neurol."},{"key":"3919_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1399-0004.2007.00934.x","volume":"73","author":"M Velinov","year":"2008","unstructured":"Velinov, M., Zellers, N., Styles, J. & Wisniewski, K. Homozygosity for mutation G212A of the gene for aspartoacylase is associated with atypical form of Canavan\u2019s disease. Clin. Genet. 73, 288\u2013289 (2008).","journal-title":"Clin. Genet."},{"key":"3919_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0046-8177(73)80098-X","volume":"4","author":"M Adachi","year":"1973","unstructured":"Adachi, M., Schneck, L., Cara, J. & Volk, B. W. Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan\u2019s disease). A review. Hum. Pathol. 4, 331\u2013347 (1973).","journal-title":"Hum. Pathol."},{"key":"3919_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ajmg.1320290234","volume":"29","author":"R Matalon","year":"1988","unstructured":"Matalon, R. et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am. J. Med. Genet. 29, 463\u2013471 (1988).","journal-title":"Am. J. Med. Genet."},{"key":"3919_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0887-8994(97)00185-9","volume":"18","author":"EC Traeger","year":"1998","unstructured":"Traeger, E. C. & Rapin, I. The clinical course of Canavan disease. Pediatr. Neurol. 18, 207\u2013212 (1998).","journal-title":"Pediatr. Neurol."},{"key":"3919_CR13","unstructured":"Bokhari, M. R., Samanta, D. & Bokhari, S. R. A. Canavan Disease (StatPearls Publishing, 2024)."},{"key":"3919_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1469-8749.1993.tb11649.x","volume":"35","author":"N Zelnik","year":"1993","unstructured":"Zelnik, N. et al. Protracted clinical course for patients with Canavan disease. Dev. Med Child Neurol. 35, 355\u2013358 (1993).","journal-title":"Dev. Med Child Neurol."},{"key":"3919_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1023\/A:1022091223498","volume":"25","author":"BJ Zeng","year":"2002","unstructured":"Zeng, B. J. et al. Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. J. Inherit. Metab. Dis. 25, 557\u2013570 (2002).","journal-title":"J. Inherit. Metab. Dis."},{"key":"3919_CR16","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1089\/104303402760128612","volume":"13","author":"C Janson","year":"2002","unstructured":"Janson, C. et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum. Gene Ther. 13, 1391\u20131412 (2002).","journal-title":"Hum. Gene Ther."},{"key":"3919_CR17","doi-asserted-by":"publisher","first-page":"165ra3","DOI":"10.1126\/scitranslmed.3003454","volume":"4","author":"P Leone","year":"2012","unstructured":"Leone, P. et al. Long-term follow-up after gene therapy for Canavan disease. Sci. Transl. Med. 4, 165ra3 (2012).","journal-title":"Sci. Transl. Med."},{"key":"3919_CR18","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.omtm.2021.01.009","volume":"20","author":"JS Francis","year":"2021","unstructured":"Francis, J. S. et al. Preclinical biodistribution, tropism, and efficacy of oligotropic AAV\/Olig001 in a mouse model of congenital white matter disease. Mol. Ther. Methods Clin. Dev. 20, 520\u2013534 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3919_CR19","doi-asserted-by":"publisher","first-page":"11537","DOI":"10.1523\/JNEUROSCI.1490-08.2008","volume":"28","author":"M Traka","year":"2008","unstructured":"Traka, M. et al. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. J. Neurosci. 28, 11537\u201311549 (2008).","journal-title":"J. Neurosci."},{"key":"3919_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ana.25674","volume":"87","author":"V Hull","year":"2020","unstructured":"Hull, V. et al. Antisense oligonucleotide reverses leukodystrophy in Canavan disease mice. Ann. Neurol. 87, 480\u2013485 (2020).","journal-title":"Ann. Neurol."},{"key":"3919_CR21","doi-asserted-by":"publisher","first-page":"14501","DOI":"10.1523\/JNEUROSCI.1056-15.2015","volume":"35","author":"H Maier","year":"2015","unstructured":"Maier, H., Wang-Eckhardt, L., Hartmann, D., Gieselmann, V. & Eckhardt, M. N-Acetylaspartate synthase deficiency corrects the myelin phenotype in a Canavan disease mouse model but does not affect survival time. J. Neurosci. 35, 14501\u201314516 (2015).","journal-title":"J. Neurosci."},{"key":"3919_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s11064-018-2693-6","volume":"45","author":"D Pleasure","year":"2020","unstructured":"Pleasure, D. et al. Pathophysiology and treatment of Canavan disease. Neurochem. Res. 45, 561\u2013565 (2020).","journal-title":"Neurochem. Res."},{"key":"3919_CR23","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.3174\/ajnr.A5398","volume":"38","author":"A McAllister","year":"2017","unstructured":"McAllister, A. et al. Quantitative synthetic MRI in children: normative intracranial tissue segmentation values during development. Am. J. Neuroradiol. 38, 2364\u20132372 (2017).","journal-title":"Am. J. Neuroradiol."},{"key":"3919_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1055\/s-2006-924734","volume":"37","author":"CG Janson","year":"2006","unstructured":"Janson, C. G. et al. Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI. Neuropediatrics 37, 209\u2013221 (2006).","journal-title":"Neuropediatrics"},{"key":"3919_CR25","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Eng. J. Med. 377, 1713\u20131722 (2017).","journal-title":"N. Eng. J. Med."},{"key":"3919_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ymgme.2018.12.003","volume":"126","author":"CB Whitley","year":"2019","unstructured":"Whitley, C. B. et al. Final results of the phase 1\/2, open-label clinical study of intravenous recombinant human N-acetyl-\u03b1-d-glucosaminidase (SBC-103) in children with mucopolysaccharidosis IIIB. Mol. Genet. Metab. 126, 131\u2013138 (2019).","journal-title":"Mol. Genet. Metab."},{"key":"3919_CR27","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/BF01799929","volume":"14","author":"C Jakobs","year":"1991","unstructured":"Jakobs, C. et al. Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease. J. Inherit. Metab. Dis. 14, 653\u2013660 (1991).","journal-title":"J. Inherit. Metab. Dis."},{"key":"3919_CR28","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/brain\/awp087","volume":"132","author":"K Kolodziejczyk","year":"2009","unstructured":"Kolodziejczyk, K., Hamilton, N. B., Wade, A., K\u00e1rad\u00f3ttir, R. & Attwell, D. The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes. Brain 132, 1496\u20131508 (2009).","journal-title":"Brain"},{"key":"3919_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.omtm.2023.06.001","volume":"30","author":"M Corti","year":"2023","unstructured":"Corti, M. et al. Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation. Mol. Ther. Methods Clin. Dev. 30, 303\u2013314 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3919_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01659-3","volume":"16","author":"A Bley","year":"2021","unstructured":"Bley, A. et al. The natural history of Canavan disease: 23 new cases and comparison with patients from literature. Orphanet J. Rare Dis. 16, 227 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"3919_CR31","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3171\/2013.8.JNS13250","volume":"120","author":"CG Janson","year":"2014","unstructured":"Janson, C. G., Romanova, L. G., Rudser, K. D. & Haines, S. J. Improvement in clinical outcomes following optimal targeting of brain ventricular catheters with intraoperative imaging. J. Neurosurg. 120, 684\u2013696 (2014).","journal-title":"J. Neurosurg."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03919-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03919-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03919-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:13:21Z","timestamp":1763140401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03919-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3919"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03919-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.L. is a shareholder of and paid consultant for Myrtelle, Inc. R.M.L. and J.F. report no conflicts of interest. C.G.J., D.S. and K.M.C. are paid consultants for Myrtelle, Inc. O.F. is co-chief medical officer and a shareholder of Myrtelle, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}